Allogene Therapeutics, Inc. (NASDAQ:ALLO - Get Free Report) SVP Annie Yoshiyama sold 9,601 shares of the stock in a transaction on Monday, April 21st. The stock was sold at an average price of $1.41, for a total value of $13,537.41. Following the sale, the senior vice president now directly owns 130,663 shares in the company, valued at approximately $184,234.83. This trade represents a 6.84 % decrease in their ownership of the stock. The transaction was disclosed in a filing with the SEC, which is available through this link.
Allogene Therapeutics Stock Up 1.3 %
Shares of ALLO stock opened at $1.61 on Thursday. Allogene Therapeutics, Inc. has a twelve month low of $1.23 and a twelve month high of $3.78. The stock's fifty day simple moving average is $1.74 and its 200 day simple moving average is $2.07. The firm has a market capitalization of $349.80 million, a P/E ratio of -1.03 and a beta of 0.99.
Allogene Therapeutics (NASDAQ:ALLO - Get Free Report) last announced its quarterly earnings results on Thursday, March 13th. The company reported ($0.28) EPS for the quarter, beating analysts' consensus estimates of ($0.34) by $0.06. As a group, equities research analysts expect that Allogene Therapeutics, Inc. will post -1.28 EPS for the current fiscal year.
Hedge Funds Weigh In On Allogene Therapeutics
Institutional investors and hedge funds have recently added to or reduced their stakes in the business. Cibc World Markets Corp acquired a new position in shares of Allogene Therapeutics during the fourth quarter worth $26,000. PAX Financial Group LLC acquired a new stake in shares of Allogene Therapeutics during the fourth quarter worth $27,000. Wealth Enhancement Advisory Services LLC acquired a new stake in shares of Allogene Therapeutics during the first quarter worth $28,000. RPO LLC bought a new position in Allogene Therapeutics during the fourth quarter worth $31,000. Finally, Caption Management LLC acquired a new position in Allogene Therapeutics in the fourth quarter valued at $32,000. 83.63% of the stock is currently owned by institutional investors and hedge funds.
Wall Street Analyst Weigh In
ALLO has been the topic of several recent analyst reports. HC Wainwright decreased their target price on shares of Allogene Therapeutics from $9.00 to $8.00 and set a "buy" rating on the stock in a report on Wednesday, March 19th. Canaccord Genuity Group restated a "buy" rating and set a $14.00 price objective on shares of Allogene Therapeutics in a research report on Friday, March 14th. Royal Bank of Canada restated an "outperform" rating and set a $10.00 target price on shares of Allogene Therapeutics in a research note on Friday, March 14th. Finally, Citizens Jmp upgraded Allogene Therapeutics from a "market perform" rating to an "outperform" rating and set a $5.00 price target on the stock in a research note on Friday, March 14th. One analyst has rated the stock with a hold rating and nine have given a buy rating to the company's stock. Based on data from MarketBeat, the company currently has an average rating of "Moderate Buy" and an average target price of $9.29.
View Our Latest Research Report on Allogene Therapeutics
About Allogene Therapeutics
(
Get Free Report)
Allogene Therapeutics, Inc, a clinical stage immuno-oncology company, develops and commercializes genetically engineered allogeneic T cell therapies for the treatment of cancer. It develops, manufactures, and commercializes UCART19, an allogeneic chimeric antigen receptor (CAR) T cell product candidate for the treatment of pediatric and adult patients with R/R CD19 positive B-cell acute lymphoblastic leukemia (ALL).
Featured Articles
This instant news alert was generated by narrative science technology and financial data from InsiderTrades.com in order to provide readers with the fastest and most accurate reporting. This story was reviewed by InsiderTrades.com's editorial team prior to publication. Please send any questions or comments about this story to contact@insidertrades.com.
